Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for pancreatoduodenectomy: A randomized clinical trial Journal Article
| Authors: | D'Angelica, M. I.; Ellis, R. J.; Liu, J. B.; Brajcich, B. C.; Gönen, M.; Thompson, V. M.; Cohen, M. E.; Seo, S. K.; Zabor, E. C.; Babicky, M. L.; Bentrem, D. J.; Behrman, S. W.; Bertens, K. A.; Celinski, S. A.; Chan, C. H. F.; Dillhoff, M.; Dixon, M. E. B.; Fernandez-Del Castillo, C.; Gholami, S.; House, M. G.; Karanicolas, P. J.; Lavu, H.; Maithel, S. K.; McAuliffe, J. C.; Ott, M. J.; Reames, B. N.; Sanford, D. E.; Sarpel, U.; Scaife, C. L.; Serrano, P. E.; Smith, T.; Snyder, R. A.; Talamonti, M. S.; Weber, S. M.; Yopp, A. C.; Pitt, H. A.; Ko, C. Y. |
| Article Title: | Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for pancreatoduodenectomy: A randomized clinical trial |
| Abstract: | Importance: Despite improvements in perioperative mortality, the incidence of postoperative surgical site infection (SSI) remains high after pancreatoduodenectomy. The effect of broad-spectrum antimicrobial surgical prophylaxis in reducing SSI is poorly understood. Objective: To define the effect of broad-spectrum perioperative antimicrobial prophylaxis on postoperative SSI incidence compared with standard care antibiotics. Design, Setting, and Participants: Pragmatic, open-label, multicenter, randomized phase 3 clinical trial at 26 hospitals across the US and Canada. Participants were enrolled between November 2017 and August 2021, with follow-up through December 2021. Adults undergoing open pancreatoduodenectomy for any indication were eligible. Individuals were excluded if they had allergies to study medications, active infections, chronic steroid use, significant kidney dysfunction, or were pregnant or breastfeeding. Participants were block randomized in a 1:1 ratio and stratified by the presence of a preoperative biliary stent. Participants, investigators, and statisticians analyzing trial data were unblinded to treatment assignment. Intervention: The intervention group received piperacillin-tazobactam (3.375 or 4 g intravenously) as perioperative antimicrobial prophylaxis, while the control group received cefoxitin (2 g intravenously; standard care). Main Outcomes and Measures: The primary outcome was development of postoperative SSI within 30 days. Secondary end points included 30-day mortality, development of clinically relevant postoperative pancreatic fistula, and sepsis. All data were collected as part of the American College of Surgeons National Surgical Quality Improvement Program. Results: The trial was terminated at an interim analysis on the basis of a predefined stopping rule. Of 778 participants (378 in the piperacillin-tazobactam group [median age, 66.8 y; 233 {61.6%} men] and 400 in the cefoxitin group [median age, 68.0 y; 223 {55.8%} men]), the percentage with SSI at 30 days was lower in the perioperative piperacillin-tazobactam vs cefoxitin group (19.8% vs 32.8%; absolute difference, -13.0% [95% CI, -19.1% to -6.9%]; P <.001). Participants treated with piperacillin-tazobactam, vs cefoxitin, had lower rates of postoperative sepsis (4.2% vs 7.5%; difference, -3.3% [95% CI, -6.6% to 0.0%]; P =.02) and clinically relevant postoperative pancreatic fistula (12.7% vs 19.0%; difference, -6.3% [95% CI, -11.4% to -1.2%]; P =.03). Mortality rates at 30 days were 1.3% (5/378) among participants treated with piperacillin-tazobactam and 2.5% (10/400) among those receiving cefoxitin (difference, -1.2% [95% CI, -3.1% to 0.7%]; P =.32). Conclusions and Relevance: In participants undergoing open pancreatoduodenectomy, use of piperacillin-tazobactam as perioperative prophylaxis reduced postoperative SSI, pancreatic fistula, and multiple downstream sequelae of SSI. The findings support the use of piperacillin-tazobactam as standard care for open pancreatoduodenectomy. Trial Registration: ClinicalTrials.gov Identifier: NCT03269994. © 2023 American Medical Association. All rights reserved. |
| Keywords: | adult; controlled study; treatment outcome; aged; major clinical study; united states; preoperative care; follow up; pancreaticoduodenectomy; randomized controlled trial; incidence; drug effect; sex ratio; health care quality; antiinfective agent; anti-bacterial agents; multicenter study; surgical infection; sepsis; surgical mortality; aging; phase 3 clinical trial; health care organization; antibiotic prophylaxis; canada; pancreatic fistula; piperacillin plus tazobactam; surgical wound infection; pancreas fistula; mortality rate; piperacillin; humans; human; male; female; article; cefoxitin; penicillanic acid; piperacillin, tazobactam drug combination |
| Journal Title: | JAMA - Journal of the American Medical Association |
| Volume: | 329 |
| Issue: | 18 |
| ISSN: | 0098-7484 |
| Publisher: | American Medical Association |
| Date Published: | 2023-05-09 |
| Start Page: | 1579 |
| End Page: | 1588 |
| Language: | English |
| DOI: | 10.1001/jama.2023.5728 |
| PUBMED: | 37078771 |
| PROVIDER: | scopus |
| PMCID: | PMC10119777 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding author is MSK author Michael I D'Angelica -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
121Seo -
1030Gonen -
172Zabor -
779D'Angelica -
10Ellis
Related MSK Work